Return to homepagePandemic Pact

Nitazoxanide for mild to moderate COVID-19 in HIV-infected and HIV uninfected adults with enhanced risk: a double-blind, randomized, placebo-controlled trial in a resource-poor setting (Catalysing the Containment of COVID-19; the C3-RCT)

  • Funded by South African Medical Research Council (SAMRC)
  • Total publications:0 publications
Grant search

Key facts

  • Disease

    COVID-19

  • Known Financial Commitments (USD)

    $1,049,937

  • Funder

    South African Medical Research Council (SAMRC)

  • Principal Investigator

    N/A

  • Research Location

    South Africa

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Clinical trial (unspecified trial phase)

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Randomized Controlled Trial

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)

  • Vulnerable Population

    Individuals with multimorbidityOtherUnspecified

  • Occupations of Interest

    Unspecified

Abstract